Hikma says it is breaking new ground in the US with a ready-to-use presentation of labetalol. Meanwhile, the company has also added hydralazine to its list of recent injectables launches.
Hikma has claimed a first in the US with the launch of its ready-to-use presentation of labetalol.
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
Already a subscriber?
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
With discounts reaching up to 90%, ustekinumab biosimilars have eroded originator Stelara’s sales as expected. In its latest quarterly biosimilar market report, Samsung Bioepis also analyzed the latest regulatory steps to streamline biosimilar development.
Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.
